Merck Reaches Multi-Billion Dollar Licensing Deal with Daiichi Sankyo for New Cancer Meds
- October 27, 2023
In a bid to bolster its oncology drug portfolio, Merck & Co. reached an agreement with Daiichi Sankyo to jointly develop three of its antibody cancer therapies in a deal worth up to $22 million for the Japanese drug maker, the two companies announced October 19.
ARTICLE TAGS
You must be logged in to access this content.